144035-83-6

Usage

Uses

Used in Respiratory Disease Treatment:
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a therapeutic agent for respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). It works by inhibiting PDE4, which leads to the reduction of inflammation and improved lung function in patients suffering from these conditions.
Used in Pre-term Infant Treatment:
In the medical field, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a treatment option for pre-term infants with bronchopulmonary dysplasia (BPD). Its PDE4 inhibitory properties help in managing the symptoms and improving the overall health of these infants.
Used in Pharmaceutical Industry:
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a key compound in the development of new drugs targeting various diseases, including respiratory and inflammatory conditions. Its potent PDE4 inhibitory activity makes it a valuable asset in the pharmaceutical industry for creating innovative therapeutic solutions.

InChI:InChI=1/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)

Upstream product

• 22889-78-7 3,5-dichloro-4-aminopyridine 
• 144036-19-1 3-cyclopentyloxy-4-methoxy benzoic acid chloride 
• 621-59-0 isovanillin 
• 137-43-9 Cyclopentyl bromide 
• 33216-52-3 3,4,5-trichloropyridine 
• 158429-58-4 3-(cyclopentyloxy)-4-methoxybenzamide 
• 144036-17-9 3-cyclopentyloxy-4-methoxy benzoic acid 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 

Downstream Products

• 171802-50-9 N-(3,5-dichloro-pyridin-4-yl)-4-methoxy-3-(tetrahydro-furan-3-yloxy)benzamide 
• 144035-96-1 N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxy(thiobenzamide) 
• 180991-82-6 N-Benzyl-N'-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamidine 

Relevant academic research and scientific papers

Cancer treatment method

The invention relates to a method for treating cancer including administering to a mammal therapeutically effective amounts of an anti-neoplastic agent and a PDE4 inhibitor, treatment combinations containing the same as well as a method for attenuating unwanted cancer treatment side effects including myelosuppression and mucositis.

COMPOUNDS CONTAINING PHENYL LINKED TO ARYL OR HETEROARYL BY AN ALIPHATIC- OR HETEROATOM-CONTAINING LINKING GROUP

This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase

Process development of the PDE IV inhibitor 3-(cyclopentyloxy)-n-(3,5-dichloropyrid-4-yl)-4-methoxybenzamide

Development of an industrial process for 3-(cyclopentyloxy)-N-(3,5-dichloropyrid-4-yl)-4-methoxybenzamide, a potent PDE IV type inhibitor, is described. The rapid identification of scalable reaction conditions allowed pilot-scale synthesis of kilogramme quantities for early clinical evaluation. However, as more compound was demanded, better reaction conditions were required in the interests of safety, economics, and environmental impact. This led to the derivation of a high-yielding and very robust procedure which included various safeguards to ensure that high-quality product was obtained and that new trace impurities were effectively removed. The large-scale oxidation of a benzaldehyde derivative to the corresponding benzoic acid using hydrogen peroxide under aqueous alkaline conditions is described.

Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group

This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues

The syntheses and biological activities of a number of benzamide derivatives, designed from rolipram, which are selective inhibitors of cyclic AMP-specific phosphodiesterase (PDE IV), are described.The effects of changes to the alkoxy groups, amide linkag

PHENYLCARBOXAMIDE COMPOUNDS WHICH HAVE USEFUL PHARMACEUTICAL ACITVITY

Compounds of formula (1) are described wherein Y represents a halogen atom or a group -OR1 where R1 represents an optionally substituted alkyl group; R2 represents an optionally substituted cyclonlkylcycloalkeny1 or polycycloalkyl group; R3 represents a hydrogen atom or an alkyl, aryl or aralkyl group; R4 represents an aryl or heteroaryl group; X represents -O-, -S-, -CH2- or -N(R5)-, where RS is a hydrogen atom or an alkyl group; n is zero or an integer or value 1, 2 or 3; and the salts, solvates and hydrates thereof. The compounds are selective phosphodiesterase IV inhibitors and are useful for the prophylaxis or treatment of inflammatory diseases